ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
LC3 and beclin-1 immunohistochemical and gene expressions in bladder cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Muscle invasion in bladder cancer is associated with increased expression of ATG5, LC3A and CHOP.Molecular biology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Egypt, bladder cancer is the second most common cancer among men and the fourth most common cancer in the population. It is tightly associated with genetic alterations. Microtubule-associated protein 1 light chain 3B (LC3) is a unique marker of autophagosomes. Beclin-1 participates in the formation of the autophagosome by mediating the localization of other autophagy proteins to the membrane of the pre-autophagosome. Impaired autophagy is linked to the development of several diseases as cancer and autoimmunity. This work aims to investigate the significance of LC3 and beclin-1 immunohistochemical and gene expressions in bladder cancer diagnosis.
methodsThis study included seventy-four tissue samples of primary urothelial bladder cancer. The tissues were investigated for gene expression, as well as histopathological and immunohistochemical analysis. The genetic and immunohistochemical expressions were correlated with the clinicopathological data.
resultsIn the cancerous tissues, there were significant upregulations of LC3 and beclin-1 mRNA and protein expression compared to the adjacent control tissues (P < 0.001 for each). A non-significant positive correlation between LC3 and beclin-1 expression was detected (r =0.212 , P=0.21). Receiver operating curve (ROC) results showed that LC3 at a cut-off point of ≥ 4.3 could be a potential diagnostic marker of bladder cancer with a sensitivity of 96.2% and a specificity of 90.6% (P < 0.001). In addition, beclin-1 at a cut-off point ≥ 2.3 could be a predictor of bladder cancer with a sensitivity of 98% and a specificity of 89% (P < 0.001).
conclusionLC3 and beclin-1 expressions can be possible diagnostic markers of bladder cancer. Additionally, they are associated with tumor grade and stage.
Indexed as
Identifiers
40762938What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.